PRIMARY PROPHYlAXIS
Co-trimoxazole intolerance is common in late disease and usually presents as a maculopapular rash. Many intolerant patients may continue to receive co-trimoxazole with the addition of an antihistamine unless there are systemic symptoms or mucosal involvement. If co-trimoxazole therapy is discontinued, desensitisation or rechallenge appear to be safe unless there are systemic symptoms or mucosal involvement. Because co-trimoxazole reduces the incidence of many opportunistic infections, rechallenge or desensitisation should be considered. Studies have demonstrated that desensitisation and rechallenge appear safe. Both rechallenge and desensitisation should be done under antihistamine cover starting the day before. Rechallenge should be done with co-trimoxazole 480 mg and the patient observed for several hours. Several desensitisation regimens exist; one of the simplest uses co- 
CO-TRIMOXAZOLE INTOLERANCE

THE PREVENTION AND TREATMENT OF OPPORTUNISTIC INFECTIONS IN HIV-INFECTED ADULTS
The best method of preventing opportunistic infections in HIV-infected individuals is to use highly active antiretroviral therapy, which leads to partial immune reconstitution. However, even if antiretroviral therapy is available a substantial proportion of patients will either present with severe immune suppression or remain severely immune-suppressed despite antiretroviral therapy. Many opportunistic infections can be prevented in these patients by using primary prophylaxis (see below) or vaccination (see below). Relapses are common after initial treatment of many opportunistic infections and maintenance therapy (also known as secondary prophylaxis -see A number of lengthy and comprehensive articles and guidelines exist with regard to the treatment and prevention of opportunistic infections, but this guideline is designed to be easy and simple for a practitioner to use. It is presented in a simplified format. The guideline is supported by evidence-based studies and adapted to be appropriate to the local situation. It should be noted that only the drugs that are licensed in South Africa have been recommended and in addition, at all times, the most cost-effective regiments) have been endorsed. Alternative regiments) have been listed where appropriate, but these are not exhaustive. A practitioner dealing with a more complex problem may find it necessary to consult with a colleague or refer to more comprehensive material. 
Bacterial pneumonia
Cefuroxime 750 mg -1.5 g tid IV' 5 -10 days Not recommended Ceramandole 1 -2 9 qid IV' Ceftriaxone 1 -2 9 daily IV' Cefotaxime 1 -2 9 bid IV' Co-amoxielav 1. should be completed with oral antibiotics (amoxicillin, co-amoxiclav, moxifloxacin or gatifloxacin are recommended) . These antibiotics are recommended in the South African Thoracic Society guidelines on community-acquired pneumonia (in pressl.
6.
A test dose of 1 mg should be given over 30 minutes If this is tolerated then half the daily dose can be infused over 4 hours with the full dose given the next day. Many experts omit the test dose. 
VACCINATION
Aerosolised pentamidine is not cost effective in the local setting.
Live vaccines should generally be avoided in adults. Yellow fever vaccine may be safe if the CD4+ count is > 200. When the C04+ count is < 200 antigenic responses tend to be poor and short-lived for all types of vaccinations. A transient increase in viral load, experienced following vaccination, can be discounted.
• Influenza vaccination should be administered annually.
• The present 23 polyvalent pneumococcal vaccine should be avoided as there is strong evidence that it is harmful. Further trials on other pneumococcal vaccines are awaited.
• Hepatitis B vaccine should be administered to hepatitis B surface antigen-negative patients.
